Professor David Price
Chair of Primary Care Respiratory Med
- About
-
- Email Address
- d.price@abdn.ac.uk
- Telephone Number
- +44 (0)1224 437237
- School/Department
- School of Medicine, Medical Sciences and Nutrition
- Publications
-
Page 1 of 96 Results 1 to 10 of 958
Chronic obstructive pulmonary disease and risk of incident cardiovascular disease, chronic kidney disease, and death: Systematic review and meta-analysis
EClinicalMedicine, vol. 98, 104131Contributions to Journals: ArticlesImplementing Quality Improvement for Patients with High-risk Chronic Disease: Lessons from the CONQUEST UK COPD Programme
Primary Health Care Research and DevelopmentContributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1017/S1463423626101480
Projecting the 20-Year Healthcare Resource Burden of Asthma and COPD Multimorbidity: Insights from Singapore for Integrated Chronic Respiratory Care in South-East Asia
npj Primary Care Respiratory Medicine, vol. 36, 36Contributions to Journals: ArticlesPatient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real-world cohort from ISAR: D1.150
EAACI Annual Congress 2026Contributions to Conferences: PostersPrevalence of type 2 multimorbidities in COPD compared to asthma and relationship to blood eosinophilic counts
ERJ Open ResearchContributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1183/23120541.00252-2026
Projecting the 20-Year Healthcare Resource Burden of Asthma and COPD Multimorbidity: Insights from Singapore for Integrated Chronic Respiratory Care in South-East Asia
ERJ Open ResearchContributions to Journals: ArticlesInvestigating differences in the implementation and experience of the Enhanced Health in Care Homes Framework in England: a qualitative protocol for the Understanding Variation in Admissions from Care Homes (UVAC) study
BMJ Open, vol. 16, no. 5, e112414Contributions to Journals: ArticlesA32-09 Beclometasone/Formoterol (BDP/FF) Is Non-inferior to Budesonide/Formoterol (BUD/FF) as Maintenance and Reliever Therapy (MART) and Reduces Inhaler-related GHG Emissions in Adult Asthma
ATS International Conference 2026, aamag162.304Contributions to Journals: AbstractsC14-07 Remission After Biologic Therapy Initiation in Patients With Severe Asthma: An Evaluation of up to 5 Years of Follow-up in the International Severe Asthma Registry
ATS International Conference 2026, aamag162.526Contributions to Journals: AbstractsC33-03 Long-Term Clinical Impact of 12-Month Remission After Biologic Therapy in Patients With Severe Asthma
ATS International Conference 2026, aamag162.562Contributions to Journals: Abstracts